First Week of January 2017 Options Trading For Rigel Pharmaceuticals (RIGL)

Investors in Rigel Pharmaceuticals Inc ( RIGL) saw new options become available this week, for the January 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the RIGL options chain for the new January 2017 contracts and identified the following put contract of particular interest.

The put contract at the $2.50 strike price has a current bid of 25 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $2.50, but will also collect the premium, putting the cost basis of the shares at $2.25 (before broker commissions). To an investor already interested in purchasing shares of RIGL, that could represent an attractive alternative to paying $2.80/share today.

Because the $2.50 strike represents an approximate 11% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 69%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 10.00% return on the cash commitment, or 61.86% annualized — at Stock Options Channel we call this the YieldBoost.

START SLIDESHOW:
Top YieldBoost Puts of the S&P 500 »

Below is a chart showing the trailing twelve month trading history for Rigel Pharmaceuticals Inc, and highlighting in green where the $2.50 strike is located relative to that history:

Loading+chart++2016+TickerTech.com

The implied volatility in the put contract example above is 127%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $2.80) to be 72%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.

If you liked this article you might like

Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers

Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers

Rigel Rises on Update on FDA Review of Bleeding Disorder Treatment

Rigel Rises on Update on FDA Review of Bleeding Disorder Treatment

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Biotech Movers: Clovis, Seattle Genetics, Rigel

Biotech Movers: Clovis, Seattle Genetics, Rigel

Arena Takes a Beating After Lackluster Secondary, Cytokinetics Pops: Biotech Movers

Arena Takes a Beating After Lackluster Secondary, Cytokinetics Pops: Biotech Movers